Eli Lilly in advanced clinical trials for its weight-loss pill

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with type-two diabetes and obesity or overweight at an increased cardiovascular risk. The company's spokesperson in India mentioned ongoing clinical studies on novel products, including orforglipron.
Source: The Economic Times - Category: Consumer Health News Source Type: news